Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05108519 · ClinicalTrials.gov registry record

Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
170
Enrollment target
1
Study location

NCT05108519 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 170 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05108519, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
170 participants
Enrollment target
1
Study location

Study Summary

This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.

Interventions

  • OTHER Electronic Health Record Review

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2019-04-08
Est. Completion 2027-02-02

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT05108519

The ClinicalTrials.gov registry entry for NCT05108519 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (85% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Electronic Health Record Review is the first listed.

NCT05108519 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05108519 about?

NCT05108519 is a clinical study titled "Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies". This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn ...

What is the current status of trial NCT05108519?

This trial is currently recruiting. The enrollment target is 170 participants. The study started on 2019-04-08. Estimated completion is 2027-02-02.

What conditions does trial NCT05108519 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT05108519?

The interventions under investigation include: Electronic Health Record Review (OTHER).

Who is sponsoring clinical trial NCT05108519?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05108519 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.